Contents:

Autoimmune Market Outlook to 2012 Executive Summary Patient potential Global market analysis Pipeline analysis Competitive landscape Chapter 1 Epidemiology of the Autoimmune therapeutic area Summary Introduction Osteoarthritis and rheumatoid arthritis Overview Diagnosis, treatment and management Epidemiology Forecast epidemiology Spondyloarthropathies Overview Diagnosis, treatment and management Epidemiology Forecast epidemiology Lupus Overview Diagnosis, treatment and management Epidemiology Forecast epidemiology Psoriasis Overview Diagnosis, treatment and management Epidemiology Forecast epidemiology Crohn’s disease Overview Diagnosis, treatment and management Epidemiology Forecast epidemiology Chapter 2 Global Market Analysis Summary Introduction Market analysis by country Licensing/generics trends Market analysis by drug class Leading brands dynamics Key events in the autoimmune market Immunosuppressants Competitive dynamics of immunosuppressants Leading brands of immunosuppressants Key brands analysis Immunosuppressants sales forecasts to 2012 Antirheumatic agents Competitive dynamics of antirheumatic agents Leading brands of antirheumatic agents Key brands analysis Antirheumatic sales forecasts to 2012 NSAIDs Competitive dynamics of NSAIDs Leading brands of NSAIDs Key brands analysis NSAIDs sales forecasts to 2012 Topical antirheumatics Competitive dynamics of topical antirheumatics Leading brands of topical antirheumatics Topical antirheumatic sales forecasts to 2012 COX-II inhibitors Competitive dynamics of COX-II inhibitors Leading brands of COX-II inhibitors Key brands analysis COX-II inhibitors sales forecasts to 2012 Corticosteroids Competitive dynamics of corticosteroids Leading brands of corticosteroids Corticosteroids sales forecasts to 2012 Total autoimmune sales forecasts to 2012 Chapter 3 Pipeline Analysis Summary Introduction Key trends in R&D Biologics Combination drugs Fully human monoclonal antibodies B-cell depleting therapies The autoimmune pipeline Leading drugs in development Profiles of key pipeline products Phase III compounds Licofelone (ML3000) Cimzia (certolizumab pegol) LymphoStat-B (belimumab) Golimumab (CNTO 148) R1594 / PRO70769 (ocrelizumab) Recently marketed drugs Actemra (tocilizumab) Rituxan (rituximab) Taclonex (calcipotriene/betamethasone) Panaclar/BG-12 Pipeline forecasts Factors affecting forecasts Autoimmune pipeline forecasts Chapter 4 Competitive Landscape Summary Introduction Amgen Overview Sales focus by drug class Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Drivers of growth Resistors of growth Johnson & Johnson Overview Sales focus by drug class Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Drivers of growth Resistors of growth Pfizer Overview Sales focus by drug class Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Drivers of growth Resistors of growth Novartis Overview Sales focus by drug class Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Drivers of growth Resistors of growth Abbott Overview Sales focus by drug class Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Drivers of growth Resistors of growth Wyeth Overview Sales focus by drug class Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Drivers of growth Resistors of growth Roche Overview Sales focus by drug class Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Drivers of growth Resistors of growth Astellas Overview Sales focus by drug class Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Drivers of growth Resistors of growth Boehringer Ingleheim Overview Sales focus by drug class Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Drivers of growth Resistors of growth Schering-Plough Overview Sales focus by drug class Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Drivers of growth Resistors of growth Chapter 5 Appendix IMS data L4A0 Immunosuppressive agents M1A1 Antirheumatics, non-steroidal plain M1A2 Antirheumatics, non-steroidal combination M1A3 Coxibs M1B0 Antirheumatics, steroidal combination M1C0 Specific anti-rheumatic agents M2A0 Antirheumatics, topical Index List of Figures Figure 1.1: Typical treatment patterns in the treatment of psoriasis Figure 2.2: Global autoimmune market share by geography, 2006 Figure 2.3: Sales of types of autoimmune brands, 2005-06 Figure 2.4: Competitive dynamics of the global autoimmune market by drug class, 2006 Figure 2.5: Competitive dynamics of the leading 10 brands in the global autoimmune market, 2005-06 Figure 2.6: Competitive dynamics of the leading immunosuppressant treatments in the global autoimmune market, 2005-6 Figure 2.7: Competitive dynamics of the leading antirheumatic treatments in the global autoimmune market, 2005-6 Figure 2.8: Competitive dynamics of the leading NSAID treatments in the global autoimmune market, 2005-06 Figure 2.9: Competitive dynamics of the leading topical antirheumatic treatments in the global autoimmune market, 2005-06 Figure 2.10: Competitive dynamics of the leading COX-II treatments in the global autoimmune market, 2005-6 Figure 2.11: Competitive dynamics of the leading corticosteroid treatments in the global autoimmune market, 2005-06 Figure 3.12: Prevailing R&D approaches, 2006 Figure 3.13: The autoimmune pipeline by indication and stage of development, 2006 Figure 3.14: Leading recently launched products and late-stage R&D compounds indicated for the treatment of autoimmune disorders, 2006 Figure 4.15: Competitive dynamics of the leading players in the global autoimmune market, 2006 Figure 4.16: Amgen’s auto-immune sales, 2006 Figure 4.17: J&J’s autoimmune sales, 2006 Figure 4.18: Pfizer’s autoimmune sales, 2006 Figure 4.19: Novartis’ autoimmune sales by drug class, 2006 Figure 4.20: Abbott’s autoimmune sales by drug class, 2006 Figure 4.21: Wyeth’s autoimmune sales by drug class, 2006 Figure 4.22: Roche’s autoimmune sales by drug class, 2006 Figure 4.23: Astellas’ autoimmune salesby drug class, 2006 Figure 4.24: BI’s autoimmune salesby drug class, 2006 Figure 4.25: Schering-Plough’s autoimmune sales by drug class, 2006 List of Tables Table 1.1: Estimated prevalence of autoimmune-related diseases in the seven major pharmaceutical markets, 2006 Table 1.2: Estimated prevalence of osteoarthritis across the seven major pharmaceutical markets, 2006 Table 1.3: Estimated prevalence of rheumatoid arthritis across the seven major pharmaceutical markets, 2006 Table 1.4: Forecast prevalence of OA across the seven major markets, Table 1.5: Forecast prevalence of RA across the seven major markets, Table 1.6: Estimated prevalence of ankylosing spondylitis across the seven major pharmaceutical markets, 2006 Table 1.7: Estimated prevalence of psoriatic arthritis across the seven major pharmaceutical markets, 2006 Table 1.8: Forecast prevalence of ankylosing spondylitis across the seven major markets, 2006–12 Table 1.9: Forecast prevalence of psoriatic arthritis across the seven major markets, 2006–12 Table 1.10: Estimated prevalence of lupus across the seven major pharmaceutical markets, 2006 Table 1.11: Forecast prevalence of lupus across the seven major markets, 2006–12 Table 1.12: Estimated prevalence of psoriasis across seven major markets, 2006 Table 1.13: Forecast prevalence of psoriasis across the seven major markets, 2006-12 Table 1.14: Estimated prevalence of Crohn’s disease in the seven major pharmaceutical markets, 2006 Table 1.15: Forecast prevalence of Crohn’s disease across the seven major markets, 2006–12 Table 2.16: Breakdown of the global autoimmune market by drug class, 2002-06 Table 2.17: Leading brands in the global autoimmune market, 2005–06 Table 2.18: Leading immunosuppressant brands in the global autoimmune market, 2005–06 Table 2.19: Immunosuppressive agents sales forecast, 2006-12 Table 2.20: Leading antirheumatic brands in the global autoimmune market, 2005–06

Companies Mentioned

- Johnson & Johnson - Pfizer - Novartis - Abbott - Wyeth - Roche - Astellas - Boehringer Ingleheim - Schering-Plough